Axovant's IPO: Harbinger Of A Biotech Bubble?
This article was originally published in Start Up
In June, Axovant Sciences Ltd. launched an IPO in which its stock almost doubled on the first day of trading and its valuation approached a frothy $3 billion. And this startling performance was attributed to just one asset – an experimental compound for Alzheimer’s disease.
You may also be interested in...
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.
Roivant is focused on expanding its existing subsidiaries, building new ones and appointing top leadership teams to run them, but founder and CEO Vivek Ramaswamy has put a hold on more IPOs.
Over the past few years, frustrating instances of shortages and recalls – particularly generics – have been blamed on inferior quality control at countless suppliers of active pharmaceutical ingredients and finished products, especially those based in India and China.